0000000000471696

AUTHOR

Jan Voorberg

showing 3 related works from this author

Immunogenic hotspots in the spacer domain of ADAMTS13 in immune‐mediated thrombotic thrombocytopenic purpura

2021

International audience; Background Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is caused by anti-ADAMTS13 autoantibodies inducing a severe deficiency of ADAMTS13. Epitope mapping studies on samples obtained during acute iTTP episodes have shown that the iTTP immune response is polyclonal, with almost all patients having autoantibodies targeting the spacer domain of ADAMTS13.Objectives To identify the immunogenic hotspots in the spacer domain of ADAMTS13.Patients/methods A library of 11 full-length ADAMTS13 spacer hybrids was created in which amino acid regions of the spacer domain of ADAMTS13 were exchanged by the corresponding region of the spacer domain of ADAMTS1. Next, th…

autoantibodiesADAMTS13 Protein030204 cardiovascular system & hematologyEpitope03 medical and health sciencesEpitopes0302 clinical medicineVon Willebrand factorimmunophenotypinghemic and lymphatic diseasesHumansthrombotic thrombocytopenic purpurachemistry.chemical_classificationbiologyPurpura Thrombotic ThrombocytopenicAutoantibodyHematologyMolecular biologyADAMTS13ADAMTS133. Good healthAmino acidepitope mappingEpitope mappingchemistryPolyclonal antibodiesImmunoglobulin Gbiology.proteinDNA IntergenicAntibody[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura

2020

Recently, we showed that ADAMTS13 circulates in an open conformation during the acute phase of immune-mediated thrombotic thrombocytopenic purpura (iTTP). Although the cause of this conformational change remains elusive, ADAMTS13 is primarily closed in iTTP patients in remission with ADAMTS13 activity >50% and undetectable anti-ADAMTS13 autoantibodies, as well as after rituximab treatment, suggesting a role for anti-ADAMTS13 autoantibodies. Therefore, immunoglobulin G from 18 acute iTTP patients was purified and added to closed ADAMTS13 in healthy donor plasma. This resulted in open ADAMTS13 in 14 of 18 (78%) samples, proving that anti-ADAMTS13 autoantibodies can induce an open ADAMTS13 con…

Male0301 basic medicine[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematologymedicine.medical_specialtySettore MED/09 - Medicina InternaProtein ConformationImmunologyThrombotic thrombocytopenic purpuraADAMTS13 ProteinBiochemistryImmunoglobulin G03 medical and health sciences0302 clinical medicineVon Willebrand factorInternal medicinehemic and lymphatic diseasesmedicineHumansAutoantibodiesSubclinical infectionPurpura Thrombocytopenic IdiopathicHematology[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologybiologybusiness.industryAutoantibody[SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/HematologyCell BiologyHematologyMiddle Agedmedicine.diseaseADAMTS133. Good health030104 developmental biologyImmunologybiology.proteinFemaleRituximabRituximabbusinessBiomarkers[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies030215 immunologymedicine.drug
researchProduct

Anti-ADAMTS13 autoantibody profiling in patients with immune-mediated thrombotic thrombocytopenic purpura.

2021

Anti-A Disintegrin and Metalloproteinase with a ThromboSpondin type 1 motif, member 13 (ADAMTS13) autoantibodies cause a severe ADAMTS13 deficiency in immune-mediated thrombotic thrombocytopenic purpura (iTTP). ADAMTS13 consists of a metalloprotease (M), a disintegrin-like (D) domain, 8 thrombospondin type 1 repeats (T1-T8), a cysteine-rich (C), a spacer (S), and 2 CUB domains (CUB1-2). We recently developed a high-throughput epitope mapping assay based on small, nonoverlapping ADAMTS13 fragments (M, DT, CS, T2-T5, T6-T8, CUB1-2). With this assay, we performed a comprehensive epitope mapping using 131 acute-phase samples and for the first time a large group of remission samples (n = 50). Ne…

MetalloproteinaseThrombospondinPurpura Thrombocytopenic IdiopathicbiologyPurpura Thrombotic Thrombocytopenicbusiness.industryThrombotic thrombocytopenic purpuraAutoantibodyHematologymedicine.diseaseADAMTS13Thrombosis and HemostasisCohort StudiesThrombospondin 1Epitope mappingImmune systemImmunologymedicineDisintegrinbiology.proteinHumansbusinessAgedAutoantibodiesBlood advances
researchProduct